Pipeline

The RNA Armory® has generated a robust pipeline of differentiated therapies in autoimmune, oncologic, and respiratory disorders.

Descartes-08/Myasthenia
Descartes-15
Descartes-33
Descartes-11/Myeloma
Descartes-08/Myeloma
Descartes-15
Descartes-25
Descartes-30/ARDS
Descartes-33

Autoimmune

Myasthenia Gravis

Generalized myasthenia gravis (GMG) is a debilitating autoimmune disease affecting over 60,000 people in the U.S. Treatment of GMG requires the chronic use of toxic immunosuppressants.

More information

DESCARTES-08 is the first CAR T-cell therapy for autoimmune disease. The lead indication is generalized myasthenia gravis (GMG). Descartes-08 contains autologous CD8+ T-cells engineered with RNA chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). BCMA is expressed ubiquitously by plasma cell clones that produce pathogenic autoantibodies. Descartes-08 binds and kills these cells, eliminating the autoantibody source.

Oncology

Multiple Myeloma

Multiple myeloma is an incurable cancer that affects 30,000 additional Americans each year. Currently, combination therapy and autologous transplant remain the standard of care. However, all known treatments of multiple myeloma eventually fail, leading to relapsed disease.

More information

DESCARTES-11 is the first CAR T-cell therapy designed for frontline cancer. The lead indication is newly diagnosed multiple myeloma. Descartes-11 contains autologous CD8+ T-cells engineered with RNA chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). BCMA is highly expressed in all myeloma cells. Descartes-11 binds and kills BCMA+ myeloma cells.

Respiratory Disorders

Descartes-30

Acute Respiratory Distress Syndrome (ARDS)

ARDS is a severe complication caused by a lung injury, such as pneumonia, sepsis, or COVID-19, and impacts up to 200,000 people in the U.S. Patients with ARDS are often unable to breath on their own and may require ventilator support to help circulate oxygen in the body. ARDS has a mortality rate of over 40%.

More information

DESCARTES-30 is the first engineered cell therapy for respiratory diseases. The lead indication is Acute Respiratory Distress Syndrome (ARDS; including COVID-19 ARDS). Descartes-30 contains allogeneic (off-the-shelf) human Mesenchymal Stem Cells (MSCs) engineered to secrete two human DNases that specifically degrade Neutrophil Extracellular Traps (NETs). NETs are a key, as yet unaddressed mediator of ARDS.